SCHEMBL2861950

SCHEMBL2861950

CC(=O)Nc1nc2cnc(N(C)c3ccc(F)c(NC(=O)c4cccc(C5(C#N)CC5)c4Cl)c3)nc2s1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRAF P15056 12/20 0.61
KDR P35968 9/20 0.61
RAF1 P04049 4/20 0.51
IKBKB O14920 1/20 0.51
ERBB2 P04626 1/20 0.51
CDK1 P06493 1/20 0.51
PDGFRB P09619 1/20 0.51
KIT P10721 1/20 0.51
SRC P12931 1/20 0.51
PDGFRA P16234 1/20 0.51
FGFR3 P22607 1/20 0.51
MAP2K1 Q02750 1/20 0.51
TEK Q02763 1/20 0.51
MAPK14 Q16539 1/20 0.51
AURKB Q96GD4 1/20 0.51
PIK3CA P42336 1/20 0.34
SMO Q99835 1/20 0.34
POLB P06746 1/20 0.33
MAPT P10636 1/20 0.33
BDKRB1 P46663 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13184956 0.93 BRAF (0.53) BRAFKDRRAF1IKBKBERBB2
SCHEMBL14406859 0.90 BRAF (0.50) BRAFKDRRAF1IKBKBERBB2
SCHEMBL2853884 0.85 KDR (0.63) BRAFKDRRAF1IKBKBERBB2
SCHEMBL2853195 0.81 BRAF (0.84) BRAFKDRRAF1IKBKBERBB2
SCHEMBL13185059 0.80 BRAF (0.56) BRAFKDRRAF1IKBKBERBB2
SCHEMBL2853208 0.80 BRAF (0.81) BRAFKDRRAF1IKBKBERBB2
SCHEMBL14406900 0.79 KDR (0.56) BRAFKDRRAF1IKBKBERBB2
SCHEMBL2853738 0.78 BRAF (0.70) BRAFKDRRAF1IKBKBERBB2
SCHEMBL2858244 0.77 BRAF (0.48) BRAFKDRRAF1IKBKBERBB2
SCHEMBL2852247 0.77 BRAF (0.69) BRAFKDRRAF1IKBKBERBB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2184285-B1 HETEROCYCLIC COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2015-11-04 EP disclosed
US-8344135-B2 Heterocyclic compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-01-01 US disclosed
US-8344135-B2 Heterocyclic compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-01-01 US disclosed
US-20100249119-A1 HETEROCYCLIC COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-30 US disclosed
US-20100249119-A1 HETEROCYCLIC COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-30 US disclosed
EP-2184285-A1 HETEROCYCLIC COMPOUND AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2010-05-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249119-A1 HETEROCYCLIC COMPOUND AND USE THEREOF BRAF, NRAS, RAF1 BRAF 1/4885KDR 983/4885RAF1 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.